MRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors.

ABSTRACT:

Background

In the last decade, chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of hematologic malignancies. However, antitumor responses in solid tumors remain poor, and the difficulty in finding truly tumor-specific target antigens leads to a high risk of on-target/off-tumor toxicity. Transient modification with mRNA is gaining momentum as an alternative approach to viral transduction in order to achieve a better safety profile. On the other hand, generation of T cells secreting bispecific T cell engagers (TCEs) has been reported to outperform the antitumor efficacy of T lymphocytes expressing membrane-anchored CARs, due to the ability of the soluble TCEs to recruit unmodified bystander T cells.

Methods

We have electroporated human

SUBMITTER: Zagorac I 

PROVIDER: S-EPMC12669218 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature